The potential economic value of influenza vaccination for healthcare workers in The Netherlands

Background Despite the clinical evidence, influenza vaccination coverage of healthcare workers remains low. To assess the health economic value of implementing an influenza immunization program among healthcare workers ( HCW ) in University Medical Centers ( UMC s) in the Netherlands, a cost‐benefit model was developed using a societal perspective. Methods/Patients The model was based on a trial performed among all UMC s in the Netherlands that included both hospital staff and patients admitted to the pediatrics and internal medicine departments. The model structure and parameters estimates we... Mehr ...

Verfasser: Meijboom, Marjan J.
Riphagen‐Dalhuisen, Josien
Hak, Eelko
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Reihe/Periodikum: Influenza and Other Respiratory Viruses ; volume 12, issue 4, page 457-464 ; ISSN 1750-2640 1750-2659
Verlag/Hrsg.: Wiley
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-28808698
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://dx.doi.org/10.1111/irv.12558

Background Despite the clinical evidence, influenza vaccination coverage of healthcare workers remains low. To assess the health economic value of implementing an influenza immunization program among healthcare workers ( HCW ) in University Medical Centers ( UMC s) in the Netherlands, a cost‐benefit model was developed using a societal perspective. Methods/Patients The model was based on a trial performed among all UMC s in the Netherlands that included both hospital staff and patients admitted to the pediatrics and internal medicine departments. The model structure and parameters estimates were based on the trial and complemented with literature research, and the impact of uncertainty explored with sensitivity analyses. Results In a base‐case scenario without vaccine coverage, influenza‐related annual costs were estimated at € 410 815 for an average UMC with 8000 HCW s and an average occupancy during the influenza period of 6000 hospitalized patients. Of these costs, 82% attributed to the HCW s and 18% were patient‐related. With a vaccination coverage of 15.47%, the societal program’s savings were € 2861 which corresponds to a saving of € 270.53 per extended hospitalization. Univariate sensitivity analyses show that the results are most sensitive to changes in the model parameters vaccine effectiveness in reducing influenza‐like illness ( ILI ) and the vaccination‐related costs. Conclusion In addition to the decreased burden of patient morbidity among hospitalized patients, the effects of the hospital immunization program slightly outweigh the economic investments. These outcomes may support healthcare policymakers’ recommendations about the influenza vaccination program for healthcare workers.